Home › Cancro ovarico › Oregon
Studi clinici su Cancro ovarico nello stato di Oregon
34 studi su Cancro ovarico cercano partecipanti presso sedi nello stato di Oregon.
Città nello stato di Oregon
Testo ufficiale dello studio (inglese)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- e altri 1
In reclutamentoFase 2
Tutte le età · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- Providence Portland Medical Center /ID# 277727, Portland
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 1 ott 2026 · NCT07024784A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 02, Portland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07814248A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Portland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT05877599A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0316 - Willamette Valley Cancer Institute/Oncology Associates of Oregon, Eugene
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 29 set 2026 · NCT05128825A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Oncology Associates of Oregon, P.C. /ID# 275006, Eugene
- Compass Oncology - West - Tigard /ID# 275101, Tigard
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 29 set 2026 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Portland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05867251A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Willamette Valley Cancer Institute and Research Center /ID# 277714, Eugene
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 22 set 2026 · NCT07059845A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- USO - Oncology Associates of Oregon, P. C., Eugene
- Providence Portland Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07213804Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Providence Cancer Institute, Portland
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 15 set 2026 · NCT06915025Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Oncology Associates of Oregon, P.C., Eugene
- Providence Cancer Institute Franz Clinic, Portland
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 15 set 2026 · NCT07214779FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Asante / Heimann Cancer Center, Medford
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06303505Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Providence Cancer Institute, Portland
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 14 set 2026 · NCT06787612Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06293898A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8010), Eugene
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 3 set 2026 · NCT06824467Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Portland
In reclutamentoFase 1/2
Età da 18 a 130 · Tutti i sessi · Aggiornato il 21 ago 2026 · NCT05797168Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Oregon Health and Science University, Portland
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT07001748A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT04895709A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Site 0105, Portland
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 12 ago 2026 · NCT07546500A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT06242470A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- Bay Area Hospital, Coos Bay
- e altri 9
In reclutamento
Età da 35 a 50 · Donne · Aggiornato il 7 ago 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- e altri 11
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 ago 2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Oncology Associates of Oregon, P.C., Eugene
- Compass Oncology - Rose Quarter, Portland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Oregon Health & Science University, Portland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 lug 2026 · NCT04657068A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Oncology Associates of Oregon, P.C., Eugene
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 lug 2026 · NCT06161025Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 517, Eugene
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 16 lug 2026 · NCT06906341First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 lug 2026 · NCT05768139A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
- Providence Oncology and Hematology Care Clinic - Westside, Portland
- Providence St. Vincent Medical Center- Investigational Drug Services, Portland
- e altri 1
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT04389632Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Legacy Medical Group Gynecologic Oncology, Portland
- Providence Cancer Center Oncology, Portland
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 2 lug 2026 · NCT06819007DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA15-0, Portland
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 mag 2026 · NCT06953089cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età 40 e oltre · Tutti i sessi · Aggiornato il 20 gen 2026 · NCT05366881CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- SCRI - Northwest Cancer Specialists, P.C., Portland
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 23 dic 2025 · NCT06690775SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 28 ott 2025 · NCT03452774Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.